To identify its possible role as a regulator of GBM invasion, they administered PDZ1i (113B7), a specific inhibitor of MDA-9/Syntenin activity, 2 h before radiation treatment on each of the 4 treatment days. Here, SDCBP is linked to glioblastoma.